Ligand ID: DM2


Drugbank ID:
DB00445
(Epirubicin)
DB00997
(Doxorubicin)


Indication:
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.;Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

Get human targets for DM2 in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'DM2' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		5r84 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.59A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
GLN A 110
GLN A 127
ILE A 152
VAL A  13
1.73A9.98
None
DMS  A 402 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.62A9.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 9
SER E 937
SER E 929
GLY F 932
ILE F 931
PHE D 927
1.76A10.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 11
GLN D 949
ASN D 953
SER E 943
GLU D1182
VAL E 951
1.71A17.83
12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
GLN A 110
GLN A 127
ILE A 152
VAL A  13
1.75A15.35
None
DMS  A 402 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.66A15.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
GLU C 290
GLN C 127
PHE C   8
VAL C 303
1.50A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER C 139
GLN A 299
GLN A 127
ILE A 152
1.68A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER A 113
ILE C 152
VAL C 157
PHE C 150
1.25A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER C 284
GLU C 288
VAL A 296
PHE A 291
1.56A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER A 284
GLU A 288
VAL C 296
PHE C 291
1.58A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER D 284
GLU D 288
VAL B 296
PHE B 291
1.50A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
PHE C   3
THR C 111
GLY C 109
ASP C 289
GLN C 110
1.76A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
GLN B 110
GLN B 127
ILE B 152
VAL B  13
1.71A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER D 139
GLN B 299
GLN B 127
ILE B 152
1.69A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER B 284
GLU B 288
VAL D 296
PHE D 291
1.58A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
GLU D 290
GLN D 127
PHE D   8
VAL D 303
1.47A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER B 113
ILE D 152
VAL D 157
PHE D 150
1.27A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
GLN A 110
GLN A 127
ILE A 152
VAL A  13
1.72A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER C 113
ILE A 152
VAL A 157
PHE A 150
1.16A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER D 113
ILE B 152
VAL B 157
PHE B 150
1.21A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.80A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
GLU A 290
GLN A 127
PHE A   8
VAL A 303
1.43A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
SER B  52
GLY B 130
ILE B 132
PHE B 111
PHE B  54
1.76A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY C  72
THR C 136
GLN C 161
ILE C  75
PHE C  54
1.27A17.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m71 NSP12
(SARS-CoV-2)		4 / 8
GLU A 658
ILE A 579
VAL A 587
PHE A 480
1.24A21.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m71 NSP12
(SARS-CoV-2)		4 / 8
GLN A 698
GLN A 468
ILE A 244
VAL A 128
1.72A21.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MRA_B_DM2B204_1
(SORCIN)		6m71 NSP12
(SARS-CoV-2)		4 / 6
TYR A 483
THR A 582
ASP A 484
GLY A 485
1.60A11.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6m71 NSP12
(SARS-CoV-2)		5 / 11
VAL A 299
PHE A 348
GLU A 350
VAL A 535
ASN A 657
1.73A17.52

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m71 NSP8
(SARS-CoV-2)		4 / 8
SER B 170
GLN B 168
ILE B 132
VAL B 130
1.69A10.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
GLY A 679
THR A 680
MET A 626
GLU A 665
1.70A13.38

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
GLY A 679
THR A 680
MET A 626
ILE A 632
1.62A13.38

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1106_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m71 NSP12
(SARS-CoV-2)		5 / 11
SER A 814
MET A 756
PHE A 812
ASN A 691
ARG A 583
1.48A21.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m71 NSP12
(SARS-CoV-2)		4 / 8
SER A 709
PHE A 766
ILE A 779
PHE A 782
1.79A21.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6m71 NSP7
NSP8
(SARS-CoV-2)		4 / 8
SER C  24
GLU C  23
ILE B 185
VAL B 131
1.73A6.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 11
VAL B 115
PHE A 275
PHE A 321
GLY A 352
ASN A 314
1.77A24.81

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY A 885
THR A 887
ILE A 896
PHE A1052
ILE A 882
1.44A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MRA_B_DM2B204_1
(SORCIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PHE C1042
THR A1027
ARG C1039
GLY A1035
1.58A9.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
SER A 968
GLN A 965
GLN A1002
GLY B 999
ILE B 742
1.62A22.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
PHE C 927
GLY C 798
GLY C 799
ASN C 928
ILE B1130
1.55A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLN C1071
GLN C 926
VAL C 911
PHE C1109
1.15A22.00
NAG  C1309 ( 4.0A)
NAG  C1309 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
SER B 309
GLN B 310
ILE B 296
VAL B 276
0.93A16.30
None
None
None
GOL  B 401 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vxs NSP3
(SARS-CoV-2)		5 / 11
ASN B  15
GLN B 107
LEU B 109
SER B 111
GLU B 114
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
VAL C 595
GLN C 644
LEU C 611
VAL C 615
ASN C 616
1.69A15.90
3.38
None
NAG  C1309 (-3.7A)
None
None
NAG  C1309 (-1.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1106_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
SER A 735
PHE B 759
ASN A 960
LEU A 959
ALA C 570
1.50A22.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
PHE B 927
GLY B 798
GLY B 799
ASN B 928
ILE A1130
1.61A10.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
SER C1003
GLN C 965
GLN A1005
GLY A 999
ILE A 997
1.56A22.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY C 885
THR C 887
ILE C 896
PHE C1052
ILE C 882
1.47A10.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY B 744
THR B 739
ASN A 317
ILE B 742
PHE A 592
1.47A10.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
SER B1003
GLN B 965
GLN C1005
GLY C 999
ILE C 997
1.57A22.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
VAL B 595
GLN B 644
LEU B 611
VAL B 615
ASN B 616
1.67A15.90
3.38
None
None
None
None
NAG  B1308 (-2.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1106_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
SER B 735
PHE C 759
ASN B 960
LEU B 959
ALA A 570
1.48A22.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLN B1071
GLN B 926
VAL B 911
PHE B1109
1.11A22.46
NAG  B1311 (-4.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
VAL B 615
GLN B 644
GLY B 652
ASN B 641
ILE B 598
1.55A10.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
GLY D  71
THR D 135
GLN D 160
ILE D  74
PHE D  53
1.35A19.21
None
None
None
GOL  D 204 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 9
SER B  51
GLY B 129
ILE B 131
PHE B 110
PHE B  53
1.77A8.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY B 248
GLY B 247
PHE B 264
ILE B 281
PHE B 241
1.59A21.81
CIT  B 408 (-3.5A)
CIT  B 408 (-3.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6w02 NSP3
(SARS-CoV-2)		5 / 12
GLY A  46
GLY A  51
ASN A  37
PHE A 132
ILE A 131
1.65A21.81
APR  A 201 (-3.7A)
None
None
APR  A 201 (-3.4A)
APR  A 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FTP_B_DM2B501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w4b NSP9
(SARS-CoV-2)		5 / 9
LEU A  89
PHE A  91
GLU A  71
VAL A 103
ASN A  99
1.76A17.07
14.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w4b NSP9
(SARS-CoV-2)		5 / 11
LEU A  89
PHE A  91
GLU A  71
VAL A 103
ASN A  99
1.75A17.07
14.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
SER A7041
GLN A6847
ILE A7005
PHE A7003
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.67A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6w6y NSP3
(SARS-CoV-2)		5 / 11
VAL A 100
PHE A 116
GLY A  78
GLY A  79
ASN A 115
1.79A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  46
GLY B  51
ASN B  37
PHE B 132
ILE B 131
1.61A21.90
None
None
None
MES  B 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w6y NSP3
(SARS-CoV-2)		4 / 8
GLU B  26
PHE A 168
ILE A  18
VAL A  16
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  46
GLY A  51
ASN A  37
PHE A 132
ILE A 131
1.74A21.90
None
None
None
AMP  A 201 ( 4.3A)
AMP  A 201 ( 3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w75 NSP16
(SARS-CoV-2)		4 / 8
SER C7041
GLN C6847
ILE C7005
PHE C7003
1.31A10.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w75 NSP10
(SARS-CoV-2)		4 / 8
SER D4382
PHE D4363
ILE D4308
VAL D4350
1.78A9.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w75 NSP16
(SARS-CoV-2)		4 / 8
SER C7041
GLN C6847
ILE C6926
PHE C7003
1.70A10.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w75 NSP16
(SARS-CoV-2)		4 / 8
SER A7041
GLN A6847
ILE A7005
PHE A7003
1.33A10.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER B 294
ILE B 300
VAL B 303
PHE B 258
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER C  24
PHE C  55
VAL C  57
PHE C  31
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER B  24
PHE B  55
VAL B  57
PHE B  31
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER A  24
PHE A  55
VAL A  57
PHE A  31
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER C 294
ILE C 300
VAL C 303
PHE C 258
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
GLY C 271
GLY C 266
THR C 265
ASN C 267
GLN A 269
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FTP_B_DM2B501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		5 / 9
LEU A  88
PHE A  90
GLU A  70
VAL A 102
ASN A  98
1.68A18.70
16.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		5 / 11
LEU A  88
PHE A  90
GLU A  70
VAL A 102
ASN A  98
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wcf NSP3
(SARS-CoV-2)		5 / 12
GLY A  46
GLY A  51
ASN A  37
PHE A 132
ILE A 131
1.60A
MES  A 202 (-4.7A)
MES  A 202 (-3.3A)
None
MES  A 201 (-2.5A)
MES  A 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 11
VAL A  16
ASN A  69
LEU B  91
PHE B  92
VAL A  66
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLN A 349
GLN B 260
ILE B 320
PHE B 315
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MRA_B_DM2B204_1
(SORCIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
TYR B 298
ARG B 293
ASP B 297
GLY B 295
1.75A19.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MRA_B_DM2B204_1
(SORCIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
TYR F 298
ARG F 293
ASP F 297
GLY F 295
1.73A19.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLN F 349
GLN E 260
ILE E 320
PHE E 315
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MRA_B_DM2B204_1
(SORCIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
TYR D 298
ARG D 293
ASP D 297
GLY D 295
1.74A19.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLN E 349
GLN F 260
ILE F 320
PHE F 315
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLU D 323
PHE D 314
ILE C 304
PHE C 307
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLU A 323
PHE A 314
ILE B 304
PHE B 307
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLU B 323
PHE B 314
ILE A 304
PHE A 307
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLN B 349
GLN A 260
ILE A 320
PHE A 315
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLN D 349
GLN C 260
ILE C 320
PHE C 315
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
GLN C 349
GLN D 260
ILE D 320
PHE D 315
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
SER A7041
GLN A6847
ILE A7005
PHE A7003
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
SER C7041
GLN C6847
ILE C7005
PHE C7003
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1106_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
SER C7038
PHE C7043
LEU C6834
THR C6846
GLN C6885
1.73A16.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
SER C7041
GLN C6847
ILE C6926
PHE C7003
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY B  71
THR B 135
GLN B 160
ILE B  74
PHE B  53
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY A  71
THR A 135
GLN A 160
ILE A  74
PHE A  53
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE D 110
ILE D 131
VAL D 133
PHE D  66
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE A 110
ILE A 131
VAL A 133
PHE A  66
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE C 110
ILE C 131
VAL C 133
PHE C  66
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY C  71
THR C 135
GLN C 160
ILE C  74
PHE C  53
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE B 110
ILE B 131
VAL B 133
PHE B  66
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
SER D  51
GLY D 129
ILE D 131
PHE D 110
PHE D  53
1.79A8.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY D  71
THR D 135
GLN D 160
ILE D  74
PHE D  53
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
SER A  51
GLY A 129
ILE A 131
PHE A 110
PHE A  53
1.75A8.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
SER B  51
GLY B 129
ILE B 131
PHE B 110
PHE B  53
1.72A8.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2DR6_A_DM2A2002_1
(ACRB)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
SER C  51
GLY C 129
ILE C 131
PHE C 110
PHE C  53
1.79A8.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wkq NSP16
(SARS-CoV-2)		4 / 8
SER A7041
GLN A6847
ILE A6926
PHE A7003
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wkq NSP16
(SARS-CoV-2)		4 / 8
SER C7041
GLN C6847
ILE C6926
PHE C7003
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wkq NSP16
(SARS-CoV-2)		4 / 8
SER C7041
GLN C6847
ILE C7005
PHE C7003
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wkq NSP16
(SARS-CoV-2)		4 / 8
SER A7041
GLN A6847
ILE A7005
PHE A7003
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
GLN A 131
PHE A 124
VAL A  78
PHE A 123
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
THR B 193
GLN B 310
PHE B 342
ILE B 306
PHE B 330
1.72A
EDO  B 404 (-4.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY A 248
GLY A 247
PHE A 264
ILE A 281
PHE A 241
1.61A
U5P  A 401 ( 4.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
SER A 309
GLN A 310
GLU A 305
VAL A 276
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY B 248
GLY B 247
PHE B 264
ILE B 281
PHE B 241
1.61A
U5P  B 401 ( 4.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
THR A 193
GLN A 310
PHE A 342
ILE A 306
PHE A 330
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
SER B 198
GLN B 160
PHE B 123
PHE B 177
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
SER A 198
GLN A 160
PHE A 123
PHE A 177
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
SER B 309
GLN B 310
ILE B 296
VAL B 276
0.92A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
SER A 309
GLN A 310
ILE A 296
VAL A 276
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
SER A 208
GLU A 211
GLN A 197
VAL A 156
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
GLN B 131
PHE B 124
VAL B  78
PHE B 123
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
THR B 275
GLU B 327
GLN B 310
PHE B 342
ILE B 306
1.68A
None
EDO  B 406 (-2.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.62A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
VAL A 100
PHE A 116
GLY A  78
GLY A  79
ASN A 115
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY D  46
GLY D  51
ASN D  37
PHE D 132
ILE D 131
1.62A
APR  D 201 (-3.8A)
None
None
APR  D 201 (-3.5A)
APR  D 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  46
GLY C  51
ASN C  37
PHE C 132
ILE C 131
1.63A
APR  C 201 (-3.9A)
None
None
APR  C 201 (-3.5A)
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
VAL C 100
PHE C 116
GLY C  78
GLY C  79
ASN C 115
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  46
GLY A  51
ASN A  37
PHE A 132
ILE A 131
1.64A
APR  A 201 (-3.9A)
None
None
APR  A 201 (-3.1A)
APR  A 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
VAL D 100
PHE D 116
GLY D  78
GLY D  79
ASN D 115
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
GLN D 118
GLU D 114
ILE A  23
VAL A  49
1.61A
None
None
APR  A 201 (-4.0A)
APR  A 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY B  46
GLY B  51
ASN B  37
PHE B 132
ILE B 131
1.63A
APR  B 201 (-3.7A)
None
None
APR  B 201 (-3.6A)
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
SER A7041
GLN A6847
ILE A7005
PHE A7003
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wqd NSP8
(SARS-CoV-2)		5 / 11
GLN D 158
LEU D 169
SER D 170
GLU D 171
VAL D 186
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 11
ASN A  -1
LEU B 103
PHE A  49
GLU A  50
VAL A   6
1.50A
None
None
None
EDO  B 302 ( 4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wqd NSP8
(SARS-CoV-2)		4 / 8
SER D 170
GLN D 168
ILE D 132
VAL D 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wqd NSP8
(SARS-CoV-2)		5 / 11
GLN B 158
LEU B 169
SER B 170
GLU B 171
VAL B 186
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FTP_B_DM2B501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wqd NSP8
(SARS-CoV-2)		5 / 9
GLN D 158
LEU D 169
SER D 170
GLU D 171
VAL D 186
1.74A16.43
16.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FTP_B_DM2B501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wqd NSP8
(SARS-CoV-2)		5 / 9
GLN B 158
LEU B 169
SER B 170
GLU B 171
VAL B 186
1.72A16.43
16.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 11
ASN C  -1
LEU D 103
PHE C  49
GLU C  50
VAL C   6
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
GLU A 290
GLN A 127
PHE A   8
VAL A 303
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
SER A  24
PHE A  55
VAL A  57
PHE A  31
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER B 113
ILE A 152
VAL A 157
PHE A 150
1.18A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.60A9.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
VAL C  22
GLN A  19
SER C  15
VAL C  33
ASN C  37
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FTP_B_DM2B501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 9
GLN B 158
LEU B 169
SER B 170
GLU B 171
VAL B 186
1.69A16.06
13.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
GLN D 158
LEU D 169
SER D 170
GLU D 171
VAL D 186
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FTP_B_DM2B501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 9
GLN D 158
LEU D 169
SER D 170
GLU D 171
VAL D 186
1.67A16.06
13.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 8
GLN A  18
ILE A  91
VAL A  93
PHE A  26
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
GLY A  31
THR A  95
GLN A 120
ILE A  34
PHE A  13
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 8
GLU A 134
ILE A  91
VAL A  93
PHE A  26
1.21A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A  70
ILE A  91
VAL A  93
PHE A  26
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
SER C  33
GLU A 516
ILE A 410
VAL A 510
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 429
ILE L  34
VAL E 382
PHE E 515
1.33A
None
None
DMS  L1601 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLU H  57
ILE E 402
VAL E 350
PHE E 400
1.55A
MLI  E 908 ( 4.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 429
ILE C  34
VAL A 382
PHE A 515
1.15A
None
None
DMS  A 905 (-4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
SER B 100
PHE A 338
VAL A 524
PHE A 392
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1106_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
SER A 301
PHE A 305
PHE A   8
THR A 292
GLN A 110
1.76A15.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 429
ILE L  34
VAL E 382
PHE E 515
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLU H  57
ILE E 402
VAL E 350
PHE E 400
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLU B  57
ILE A 402
VAL A 350
PHE A 400
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 429
ILE C  34
VAL A 382
PHE A 515
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.65A15.44
None
CL  A 406 ( 3.6A)
PEG  A 405 (-3.3A)
None
PEG  A 405 ( 3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  46
GLY D  51
ASN D  37
PHE D 132
ILE D 131
1.63A
EDO  D 206 ( 4.6A)
None
None
EDO  D 205 ( 3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
VAL A 100
PHE A 116
GLY A  78
GLY A  79
ASN A 115
1.79A
None
None
None
None
EDO  D 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
VAL D 100
PHE D 116
GLY D  78
GLY D  79
ASN D 115
1.79A
None
None
None
None
EDO  D 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  46
GLY B  51
ASN B  37
PHE B 132
ILE B 131
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  46
GLY C  51
ASN C  37
PHE C 132
ILE C 131
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
VAL B  41
PHE B 132
GLY B  46
GLY E 133
ASN E 101
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  46
GLY A  51
ASN A  37
PHE A 132
ILE A 131
1.61A
None
None
None
EDO  A 202 (-3.9A)
EDO  A 202 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  46
GLY E  51
ASN E  37
PHE E 132
ILE E 131
1.58A
EPE  E 202 (-3.9A)
None
None
EPE  E 202 (-3.2A)
EPE  E 202 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  46
GLY A  51
ASN A  37
PHE A 132
ILE A 131
1.56A
APR  A 201 (-4.2A)
None
None
APR  A 201 (-3.7A)
APR  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  46
GLY C  51
ASN C  37
PHE C 132
ILE C 131
1.56A
APR  C 201 (-4.3A)
None
None
APR  C 201 (-3.5A)
APR  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  46
GLY E  51
ASN E  37
PHE E 132
ILE E 131
1.63A
APR  E 201 (-3.9A)
None
None
APR  E 201 (-3.5A)
APR  E 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  46
GLY B  51
ASN B  37
PHE B 132
ILE B 131
1.53A
EDO  B 202 (-3.9A)
None
None
APR  B 201 (-3.5A)
APR  B 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  46
GLY D  51
ASN D  37
PHE D 132
ILE D 131
1.62A
APR  D 201 (-3.8A)
None
None
APR  D 201 (-3.3A)
APR  D 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER B  65
GLN B  62
ILE B 131
VAL E 100
1.67A
None
EDO  B 202 (-4.2A)
APR  B 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  46
GLY B  51
ASN B  37
PHE B 132
ILE B 131
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  46
GLY A  51
ASN A  37
PHE A 132
ILE A 131
1.59A
MES  A 201 ( 4.9A)
None
None
MES  A 201 (-3.5A)
MES  A 201 (-4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  46
GLY C  51
ASN C  37
PHE C 132
ILE C 131
1.51A
None
None
None
MES  C 201 (-3.6A)
MES  C 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1105_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 11
PHE A   3
THR A 111
GLY A 109
ASP A 289
GLN A 110
1.66A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7btf NSP7
NSP8
(SARS-CoV-2)		4 / 8
SER C  24
GLU C  23
ILE B 185
VAL B 131
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7btf NSP12
(SARS-CoV-2)		4 / 8
GLU A 658
ILE A 579
VAL A 587
PHE A 480
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1106_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7btf NSP12
(SARS-CoV-2)		5 / 11
PHE A  45
LEU A 727
THR A 701
ALA A 702
ARG A 132
1.77A21.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 8
SER C   1
PHE A 419
VAL A 844
PHE A 843
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7btf NSP12
(SARS-CoV-2)		5 / 11
VAL A 299
PHE A 348
GLU A 350
VAL A 535
ASN A 657
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		7btf NSP12
(SARS-CoV-2)		5 / 12
GLY A 839
GLY A 841
ASN A 416
ILE A 837
PHE A 415
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_B_DM2B303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		7btf NSP12
(SARS-CoV-2)		5 / 11
PHE A 415
GLY A 839
GLY A 841
ASN A 416
ILE A 837
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MRA_B_DM2B204_1
(SORCIN)		7btf NSP12
(SARS-CoV-2)		4 / 6
TYR A 483
THR A 582
ASP A 484
GLY A 485
1.72A11.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1106_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7btf NSP12
(SARS-CoV-2)		5 / 11
SER A 814
MET A 756
PHE A 812
ASN A 691
ARG A 583
1.52A21.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		7btf NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
GLY A 679
THR A 680
MET A 626
ILE A 632
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
GLN A 110
GLN A 127
ILE A 152
VAL A  13
1.77A
None
DMS  A 406 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FTP_B_DM2B501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP8
(SARS-CoV-2)		5 / 9
GLN B 158
LEU B 169
SER B 170
GLU B 171
VAL B 186
1.68A20.27
12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP8
(SARS-CoV-2)		5 / 11
GLN B 158
LEU B 169
SER B 170
GLU B 171
VAL B 186
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP8
(SARS-CoV-2)		5 / 11
ASN D 109
GLN D 157
PHE D 147
VAL D 130
TRP D 154
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
GLU A 658
ILE A 579
VAL A 587
PHE A 480
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
GLN A 886
GLN A 875
VAL A 435
PHE A 428
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv1 NSP7
NSP8
(SARS-CoV-2)		4 / 8
SER C  24
GLU C  23
ILE B 185
VAL B 131
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
GLN A 875
GLN A 886
PHE A 422
PHE A 428
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 11
VAL A 299
PHE A 348
GLU A 350
VAL A 535
ASN A 657
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
GLN A 886
GLN A 875
VAL A 435
PHE A 428
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
VAL A 776
LEU A 749
PHE A 745
GLU A 744
VAL A 704
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_A_DM2A1106_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv2 NSP12
NSP7
(SARS-CoV-2)		5 / 11
SER C  15
PHE A 415
PHE A 843
ALA A 547
ARG A 858
1.53A6.43
None
None
None
None
U  P  17 ( 3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
SER B 170
GLN B 168
ILE B 132
VAL B 130
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
VAL A 299
PHE A 348
GLU A 350
VAL A 535
ASN A 657
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
GLN A 875
GLN A 886
PHE A 422
PHE A 428
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
SER A 709
PHE A 766
ILE A 779
PHE A 782
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM7_A_DM2A501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv2 NSP8
(SARS-CoV-2)		5 / 11
GLN B 158
LEU B 169
SER B 170
GLU B 171
VAL B 186
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 8
GLN B 157
GLU B 155
ILE B 185
VAL A 405
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FTP_B_DM2B501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv2 NSP8
(SARS-CoV-2)		5 / 9
GLN B 158
LEU B 169
SER B 170
GLU B 171
VAL B 186
1.62A20.27
12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 839
GLY A 841
ASN A 416
ILE A 837
PHE A 415
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZVM_A_DM2A303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 678
GLY A 679
THR A 680
MET A 626
ILE A 632
1.59A
None
None
F86  P 102 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
GLU A 658
ILE A 579
VAL A 587
PHE A 480
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DX7_B_DM2B1104_1
(ACRIFLAVINE
RESISTANCE PROTEIN B)		7bv2 NSP7
NSP8
(SARS-CoV-2)		4 / 8
SER C  24
GLU C  23
ILE B 185
VAL B 131
1.73A
None